A new vaccine could soon protect patients from returning skin cancer.
In a large clinical trial, patients with high-risk melanoma given an experimental vaccine alongside an approved immunotherapy drug called Keytruda were cancer free for longer than patients who received the drug alone, Moderna and Merck announced August 19. Because the vaccine is tailored to attack specific cancer cells, the tactic could offer patients a personalized treatment option if approved by regulatory agencies.
The pharmaceutical companies have not yet released data from the trial. Previous trials showed the combination treatment cut the risk of returning cancer or…
Read the full article at SCIENCENEWS.ORG
